Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAFIK ABADIER

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1649253147
CMS profile
256213
Location
INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,191.02

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,225.65 5
Food and Beverage $965.37 17

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAFIK ABADIER

NPI 1649253147 · CMS profile ID 256213

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

INVERNESS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649253147?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649253147?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649253147?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAFIK ABADIER, NPI 1649253147, CMS profile ID 256213, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1649253147?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $2,191.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $74.2109/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125168644 CMS
SCPHARMACEUTICALS INC. $15.2907/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132287828 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.3107/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118093576 CMS
Amgen Inc. $20.1906/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115405950 CMS
Novartis Pharmaceuticals Corporation $22.9706/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619753 CMS
Novartis Pharmaceuticals Corporation $73.7504/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619747 CMS
Novartis Pharmaceuticals Corporation $115.5004/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619749 CMS
Novartis Pharmaceuticals Corporation $342.7004/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619751 CMS
Novartis Pharmaceuticals Corporation $203.8104/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619757 CMS
Novartis Pharmaceuticals Corporation $140.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619755 CMS
AstraZeneca Pharmaceuticals LP $22.3203/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105285817 CMS
Novartis Pharmaceuticals Corporation $19.7803/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619739 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.1501/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118093578 CMS
PFIZER INC. $19.5901/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130954013 CMS
ModernaTX, Inc. $358.8001/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560850 CMS
ModernaTX, Inc. $191.3001/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560852 CMS
ModernaTX, Inc. $150.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560854 CMS
ModernaTX, Inc. $217.3501/04/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560856 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560858 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560860 CMS
ModernaTX, Inc. $50.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560862 CMS
ModernaTX, Inc. $25.0001/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152560864 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,012.13 30
PY2020 $285.07 11
PY2021 $127.23 4
PY2022 $153.51 10
PY2023 $3,321.33 24
PY2024 $2,191.02 22
PY2025 $222.26 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $731.79 4
PY2025 Principal investigator $554,369.24 96
PY2024 Principal investigator $1,358,878.08 258
PY2023 Principal investigator $1,095,651.17 1,020
PY2022 Principal investigator $767,493.58 1,505
PY2021 Principal investigator $331,251.89 220
PY2020 Principal investigator $152,753.28 147
PY2019 Principal investigator $85,046.12 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $74,932.31 12/31/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Noninterventional Study to Evaluate Inflammatory Biomarkers in Different Patient Populations Compared to Healthy Participants. No dispute reported 06/30/2026 1232917905
Principal investigator 1 ModernaTX, Inc. $500.00 12/26/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007055
Principal investigator 1 ModernaTX, Inc. $280.80 12/19/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976651
Principal investigator 1 ModernaTX, Inc. $1,303.40 11/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976711
Principal investigator 1 ModernaTX, Inc. $299.52 11/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976733
Principal investigator 1 ModernaTX, Inc. $4,000.00 11/10/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976677
Principal investigator 1 ModernaTX, Inc. $355.68 10/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976655
Principal investigator 1 ModernaTX, Inc. $280.80 09/29/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976703
Principal investigator 1 ModernaTX, Inc. $100.00 09/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976645
Principal investigator 1 ModernaTX, Inc. $300.00 09/17/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976715
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/01/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976725
Principal investigator 1 ModernaTX, Inc. $3,114.78 08/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976661
Principal investigator 1 ModernaTX, Inc. $355.68 08/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976701
Principal investigator 1 ModernaTX, Inc. $19.76 08/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007041
Principal investigator 1 AstraZeneca Pharmaceuticals LP $21,888.80 08/20/2025 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185538184
Principal investigator 1 Alnylam Pharmaceuticals Inc. $324.00 08/13/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518416
Principal investigator 1 Alnylam Pharmaceuticals Inc. $406.00 08/13/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 08/13/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518768
Recipient ABBVIE INC. $52.88 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202396989
Recipient ABBVIE INC. $448.45 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202396993
Recipient ABBVIE INC. $215.46 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202396980
Recipient ABBVIE INC. $15.00 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202396985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $398.00 08/07/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518752
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,001.00 08/07/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 08/07/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518771
Principal investigator 1 AstraZeneca Pharmaceuticals LP $78,651.70 08/07/2025 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185538190
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 08/01/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518748
Principal investigator 1 Merck Sharp & Dohme LLC $49,955.89 07/30/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Noninterventional Study to Evaluate Inflammatory Biomarkers in Different Patient Populations Compared to Healthy Participants. No dispute reported 06/30/2026 1232917903
Principal investigator 1 ModernaTX, Inc. $93.60 07/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976647
Principal investigator 1 ModernaTX, Inc. $1,038.26 07/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,251.00 07/14/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518758
Principal investigator 1 Amgen Inc. $48,098.03 07/14/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246644980
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,178.80 07/02/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215518744
Principal investigator 1 ModernaTX, Inc. $224.64 06/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976691
Principal investigator 1 ModernaTX, Inc. $1,303.40 06/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976709
Principal investigator 1 ModernaTX, Inc. $528.00 06/25/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007081
Principal investigator 1 ModernaTX, Inc. $1,303.40 06/18/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976713
Principal investigator 1 ModernaTX, Inc. $224.64 06/18/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976727
Principal investigator 1 ModernaTX, Inc. $418.66 06/18/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007047
Principal investigator 1 AstraZeneca Pharmaceuticals LP $700.00 06/11/2025 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185538188
Principal investigator 1 ModernaTX, Inc. $264.00 06/09/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007085
Principal investigator 1 ModernaTX, Inc. $409.50 05/29/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007051
Principal investigator 1 ModernaTX, Inc. $336.96 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976657
Principal investigator 1 ModernaTX, Inc. $1,303.40 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976731
Principal investigator 1 ModernaTX, Inc. $1,419.63 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007045
Principal investigator 1 ModernaTX, Inc. $6,975.28 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007053
Principal investigator 1 ModernaTX, Inc. $25,119.60 05/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007073
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007069
Principal investigator 1 ModernaTX, Inc. $500.00 05/23/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007079
Principal investigator 1 ModernaTX, Inc. $326.03 05/19/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976659
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976705
Principal investigator 1 ModernaTX, Inc. $2,000.00 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976649
Principal investigator 1 ModernaTX, Inc. $2,000.00 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976669
Principal investigator 1 ModernaTX, Inc. $500.00 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976681
Principal investigator 1 ModernaTX, Inc. $569.00 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976693
Principal investigator 1 ModernaTX, Inc. $9,234.51 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976695
Principal investigator 1 ModernaTX, Inc. $1,575.00 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976697
Principal investigator 1 ModernaTX, Inc. $1,372.95 05/07/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976719
Principal investigator 1 ModernaTX, Inc. $17,350.00 05/01/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976637
Principal investigator 1 ModernaTX, Inc. $550.00 05/01/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976667
Principal investigator 1 ModernaTX, Inc. $1,000.00 05/01/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults No dispute reported 06/30/2026 1252976717
Principal investigator 1 ModernaTX, Inc. $1,303.40 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976643
Principal investigator 1 ModernaTX, Inc. $318.24 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976707
Principal investigator 1 ModernaTX, Inc. $2,839.26 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007061
Principal investigator 1 ModernaTX, Inc. $10,885.16 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007063
Principal investigator 1 ModernaTX, Inc. $7,745.92 04/28/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007065
Principal investigator 1 ModernaTX, Inc. $400.00 04/17/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976735
Principal investigator 1 ModernaTX, Inc. $500.00 04/10/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007049
Principal investigator 1 ModernaTX, Inc. $9,050.00 03/25/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976729
Principal investigator 1 ModernaTX, Inc. $4,104.36 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976653
Principal investigator 1 ModernaTX, Inc. $224.64 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976687
Principal investigator 1 ModernaTX, Inc. $7,350.72 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007057
Principal investigator 1 ModernaTX, Inc. $7,098.15 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007071
Principal investigator 1 ModernaTX, Inc. $2,511.96 03/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007083
Principal investigator 1 ModernaTX, Inc. $500.00 03/20/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976679
Principal investigator 1 ModernaTX, Inc. $131.04 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976663
Principal investigator 1 ModernaTX, Inc. $1,303.40 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976683
Principal investigator 1 ModernaTX, Inc. $1,010.88 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976685
Principal investigator 1 ModernaTX, Inc. $12,347.72 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252976689
Principal investigator 1 ModernaTX, Inc. $5,678.52 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007039
Principal investigator 1 ModernaTX, Inc. $7,844.72 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007043
Principal investigator 1 ModernaTX, Inc. $3,349.28 02/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $955.00 02/21/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215518527
Principal investigator 1 AstraZeneca UK Limited $30,874.22 02/12/2025 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185538182
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,900.00 02/04/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH LLC
A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week proof of concept and dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with heart failure No dispute reported 06/30/2026 1190308438
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215520513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Nature Coast Clinical Research
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215520518
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,974.36 01/31/2025 Non-covered Recipient Entity
NATURE COAST CLINIC RESEARCH
A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi No dispute reported 06/30/2026 1185538186
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/30/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007067
Principal investigator 1 ModernaTX, Inc. $4,505.28 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007059
Principal investigator 1 ModernaTX, Inc. $5,678.52 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007077
Principal investigator 1 ModernaTX, Inc. $13,815.78 01/27/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253007087
Principal investigator 1 ModernaTX, Inc. $213.30 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976639
Principal investigator 1 ModernaTX, Inc. $486.00 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976641
Principal investigator 1 ModernaTX, Inc. $200.00 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976671
Principal investigator 1 ModernaTX, Inc. $135.00 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976673
Principal investigator 1 ModernaTX, Inc. $378.00 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976675
Principal investigator 1 ModernaTX, Inc. $202.50 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976699
Principal investigator 1 ModernaTX, Inc. $675.00 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976721
Principal investigator 1 ModernaTX, Inc. $472.50 01/24/2025 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252976723